Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 106
- Registration Number
- NCT06047184
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism
- Conditions
- Female InfertilityPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesSubclinical Hypothyroidism
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
- Target Recruit Count
- 200
- Registration Number
- NCT06041204
- Locations
- 🇪🇬
Al-Hussein University Hospital, Cairo, Egypt
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Metastatic Breast CancerHER2 Negative Breast CarcinomaBreast CancerAdvanced Breast CancerER Positive Breast Cancer
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- International Peace Maternity and Child Health Hospital
- Target Recruit Count
- 858
- Registration Number
- NCT06006091
- Locations
- 🇨🇳
Yu Xiao, Shanghai, China
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
- Conditions
- Early-stage Breast CancerBreast CancerHigh Risk Breast Carcinoma
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06001762
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Queen Savang Vadhana Memorial Hospital, Thailand
- Target Recruit Count
- 70
- Registration Number
- NCT05940233
- Locations
- 🇹🇭
Sutinee Srimahachota, Bangkok, Yannawa, Thailand
Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy
- Conditions
- Ectopic Pregnancy
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT05918718
- Locations
- 🇮🇷
Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of
A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT05909397
- Locations
- 🇸🇰
Nemocnica na okraji mesta n o, Partizanske, Slovakia
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.